|
Goncalves, Priscila H; Heilbrun, Lance K; Barrett, Michael T et al. (2017) A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma. Oncotarget 8:32918-32929
|
|
Li, Jing; Kim, Seongho; Shields, Anthony F et al. (2016) Integrating Dynamic Positron Emission Tomography and Conventional Pharmacokinetic Studies to Delineate Plasma and Tumor Pharmacokinetics of FAU, a Prodrug Bioactivated by Thymidylate Synthase. J Clin Pharmacol 56:1433-1447
|
|
LoRusso, Patricia M; Li, Jing; Burger, Angelika et al. (2016) Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors. Clin Cancer Res 22:3227-37
|
|
Boerner, Julie L; Nechiporchik, Nicole; Mueller, Kelly L et al. (2015) Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer. PLoS One 10:e0119614
|
|
Busaidy, Naifa L; LoRusso, Patricia; Lawhorn, Kristie et al. (2015) The Prevalence and Impact of Hyperglycemia and Hyperlipidemia in Patients With Advanced Cancer Receiving Combination Treatment With the Mammalian Target of Rapamycin Inhibitor Temsirolimus and Insulin Growth Factor-Receptor Antibody Cixutumumab. Oncologist 20:737-41
|
|
Li, Jing; Kim, Seongho; Sha, Xianyi et al. (2014) Complex disease-, gene-, and drug-drug interactions: impacts of renal function, CYP2D6 phenotype, and OCT2 activity on veliparib pharmacokinetics. Clin Cancer Res 20:3931-44
|
|
Liu, Xiaochun; Lorusso, Patricia; Mita, Monica et al. (2014) Incidence of mucositis in patients treated with temsirolimus-based regimens and correlation to treatment response. Oncologist 19:426-8
|
|
Abrams, Jeffrey S; Mooney, Margaret M; Zwiebel, James A et al. (2013) Implementation of timeline reforms speeds initiation of National Cancer Institute-sponsored trials. J Natl Cancer Inst 105:954-9
|
|
Naing, A; Lorusso, P; Fu, S et al. (2013) Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma. Br J Cancer 108:826-30
|
|
Wu, Jianmei; Wiegand, Richard; LoRusso, Patricia et al. (2013) A stable isotope-labeled internal standard is essential for correcting for the interindividual variability in the recovery of lapatinib from cancer patient plasma in quantitative LC-MS/MS analysis. J Chromatogr B Analyt Technol Biomed Life Sci 941:100-8
|
Showing the most recent 10 out of 48 publications
